About Us

The MESSAGE project aims to create policies ensuring biomedical, health and care researchers consider both sex and gender in their work.

About MESSAGE

The aim of the MESSAGE (Medical Science Sex and Gender Equity) project is:

To co-design and implement a policy framework for funders and regulators which will ensure that biomedical, health and care researchers account for sex and gender in their funding applications and their research projects.

Flat vector abstract illustration with hand drawn textures showing female and male scientists making biochemistry research.

A policy framework will ensure research accounts for sex and gender across every stage of the research cycle, from study design and recruitment to data analysis and reporting of findings.

Study Design

Recruitment

Data Analysis

Reporting of Findings

Under “biomedical, health and care research” we include basic (cell/animal), clinical and population research.​​

Under “sex and gender policies” or “policies that account for sex and gender”, we include policies focused on improving integration of sex and gender considerations in biomedical, health and care research.​​

The overall goal of MESSAGE is to realise a culture change in UK research practice to integrate sex and gender dimensions at the core of project planning and execution. Educational materials to support researchers to learn the skills required to implement these changes within their own work will be launched on this website in 2024.

Why Sex and Gender?

Sex and gender affect our experience of illness, the conditions and symptoms we develop, how we are treated within a healthcare system, how we respond to treatment (including side effects), and our overall health outcomes. It is important to understand differences and similarities related to sex and gender to conduct accurate and safe research and improve health outcomes for all peoples.​

Evidence demonstrates that there is, and has historically been, an over-representation of male participants in biomedical research:

  • Up to 5.5 times more males than females are used in cell and animal research (Beery & Zucker, 2011)
  • In phase I clinical trials, around 20% of participants are women (Ravindran et al., 2020)

Likewise, study data is rarely disaggregated on the basis of sex and gender in reported results and statistical models largely control for sex rather than treating it as an effect modifier.

Research which doesn’t take account of sex and gender leads to less targeted care and worse outcomes for all people, but particularly for cis women, trans and intersex people, and people with variations of sex characteristics.

Abstract vector illustration depicting concept of genetic engineering and human internal organs.
CASE STUDY 1

Cardiovascular disease

Women’s symptoms of cardiovascular disease are more likely to be misdiagnosed…

CASE STUDY 2

Autism

While traditionally and to this day, it has been wrongly assumed that autism predominantly impacts men and boys…

CASE STUDY 3

Osteoporosis

Low estrogen and low testosterone in cis women and men respectively increase the risk for osteoporosis…

Realising change: Co-design for policy innovation

A policy-focused initiative

High-income countries around the world – notably Canada, the United States and European nations under Horizon Europe – have longstanding funder policies in place to ensure researchers account for sex and gender in their research design when applying for funding. By contrast, the UK currently has no standard, unified policy guidance for researchers.

Evaluations of these existing policies worldwide show their effectiveness in improving the frequency and quality of how sex and gender are accounted for in research​ (e.g., Haverfield & Tannenbaum, 2021).

Flat style easily editable and nicely layered vector illustration with hand drawn textured elements. Showing teacher and students discussing, talking, communicating, sharing opinions, looking for solutions etc.

MESSAGE is bringing together representatives from across the biomedical, health and care research sectors to co-design a policy framework for funders and regulators. This includes funding and regulatory representatives, as well as patients, researchers and publishers.

Each research study can be understood as passing down a pipeline:

Funders

Universities and
Research Institutions

Peer-reviewed Journals

Funders and regulators are the first step in the research pipeline: they decide what counts as robust study design with high external validity and therefore which studies are funded and approved. It is for this reason that MESSAGE is first designing a policy for research funders and regulators. It is essential that other members of the research sector are involved in the policy design process as it will affect their work further down the pipeline and will inform how they design and implement their own policies in due course.

To ensure the research sector is walking in step together, MESSAGE is bringing together stakeholders from across the sector to co-design a policy framework. The co-design process will occur over the course of four Policy Labs, held between May 2023 and April 2024.

A Policy Lab is a focused, collaborative workshop that brings diverse stakeholders together around a particular challenge. Discussions centre on developing new ideas and practical approaches to address the challenge, including understanding barriers and facilitators, with the ultimate aim of improving outcomes for users and patients.

Four Policy Labs will be held over 2023 and 2024:

Policy Lab 1

May 2023

Starting the conversation

Policy Lab 2

September 2023

Reviewing and refining a preliminary policy framework

Policy Lab 3

January 2024

Reviewing the final framework,
thinking about implementation

Policy Lab 4

April 2024

Reflecting on implementation so far

The MESSAGE co-design process is centred on the principles of openness, transparency and learning: ensuring that all participants’ views and lived experiences are heard and incorporated as far as possible. We are particularly grateful to be able to hear the views and experiences of our patient representatives, including trans and intersex individuals, who will ensure that policy content is relevant to the needs of the people it is intended to benefit.